Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
NeuroPace's peak revenue was $79.9M in 2024. The peak quarterly revenue was $21.5M in 2024(q4).
NeuroPace's revenue increased from $41.1m in 2020 to $79.9M currently. That's a 94.24% change in annual revenue.
| Fiscal year / year | NeuroPace revenue |
|---|---|
| 2020 | $41.1M |
| 2021 | $45.2M |
| 2022 | $45.5M |
| 2023 | $65.4M |
| 2024 | $79.9M |
How accurately did NeuroPace's revenue projections match actual performance?
NeuroPace saw the greatest revenue growth in 2021, when revenue increased by 9.83%.
NeuroPace had the lowest revenue growth in 2022, when revenue changed by 0.75%.
| Year | NeuroPace growth |
|---|---|
| 2021 | 10%↑ |
| 2022 | 1%↑ |
| 2023 | 44%↑ |
| 2024 | 22%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | - | $10.8M |
| 2021 | $11.2M | $12.6M | $10.3M | $11.0M |
| 2022 | $11.4M | $10.2M | $11.2M | $12.8M |
| 2023 | $14.5M | $16.5M | $16.4M | $18.0M |
| 2024 | $18.1M | $19.3M | $21.1M | $21.5M |
Do you work at NeuroPace?
Is NeuroPace transparent about its revenue structure?
NeuroPace received early financing of $30.0M on 2005-01-01.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $30M | 01/2005 |
| Series Unknown | $49M | 08/2011 |
| Series Unknown | $18M | 07/2013 |
| Series Unknown | $74M | 10/2017 |
| Series Unknown | $33M | 08/2020 |
| Debt Financing | $34M | 08/2020 |
| Grant | $9.3M | 06/2021 |
| Investors | Security type |
|---|---|
| MedVenture | Series Unknown |
| New Enterprise Associates (NEA) | Series Unknown |
| InterWest Partners | Series Unknown |
| Kleiner Perkins | Series Unknown |
| Technology Partners | Series Unknown |
| Domain Associates | Series Unknown |
| Johnson & Johnson Development Corporation | Series Unknown |
| Cutlass Capital LLC | Series Unknown |
| New Enterprise Associates (NEA) | Series Unknown |
| Angel Medical Systems Inc | Series Unknown |
| Kleiner Perkins | Series Unknown |
| Domain Associates | Series Unknown |
| Johnson & Johnson Development Corporation | Series Unknown |
| New Enterprise Associates (NEA) | Series Unknown |
| InterWest Partners | Series Unknown |
| MedVenture Associates | Series Unknown |
| Kleiner Perkins | Series Unknown |
| Kent, Campa and Kate, Inc. - KCK | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| Accelmed | Series Unknown |
| Soleus Capital LLC | Series Unknown |
| Kent, Campa and Kate, Inc. - KCK | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| Revelation Partners | Series Unknown |
| National Institutes of Health (NIH) | Grant |
NeuroPace's top competitor, GE Healthcare Holdings Inc., earned an annual revenue of $18.3B.
NeuroPace's smallest competitor is Guided Therapeutics with revenue of $1.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| AngioDynamics | $50,008 | $303.9M | 1,050 | 10 |
| ReVision Optics | $69,217 | $3.2M | 125 | - |
| Medtronic | $73,671 | $17.0B | 104,950 | 2,257 |
| Ivenix | $45,715 | $9.9M | 49 | 1 |
| BrainScope Company | $55,975 | $12.5M | 47 | - |
| HeartFlow | $91,504 | $70.0M | 302 | 91 |
| Senseonics | $86,194 | $22.5M | 135 | 1 |
| HeartWare International | $81,564 | $180.0M | 350 | - |
| Jadak Technologies | $72,239 | $28.3M | 125 | - |
| Hyde Engineering + Consulting | $81,482 | $17.2M | 279 | 4 |
Zippia gives an in-depth look into the details of NeuroPace, including salaries, political affiliations, employee data, and more, in order to inform job seekers about NeuroPace. The employee data is based on information from people who have self-reported their past or current employments at NeuroPace. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by NeuroPace. The data presented on this page does not represent the view of NeuroPace and its employees or that of Zippia.
NeuroPace may also be known as or be related to NEUROPACE, NeuroPace, NeuroPace Inc, NeuroPace, Inc., Neuropace and Neuropace, Inc.